Patent details

EP3781132 Title: APIXABAN FORMULATIONS

Basic Information

Publication number:
EP3781132
PCT Application Number:
US2019027456
Type:
European Patent Granted for LU
Legal Status:
In force
Application number:
EP197223332
PCT Publication Number:
WO2019204193
First applicant's nationality:
Translation Language:
EPO Publication Language:
English
English Title of Invention:
APIXABAN FORMULATIONS
French Title of Invention:
FORMULATIONS D'APIXABAN
German Title of Invention:
APIXABAN-FORMULIERUNGEN
SPC Number:

Dates

Filing date:
15/04/2019
Grant date:
20/03/2024
EP Publication Date:
24/02/2021
PCT Publication Date:
24/10/2019
Claims Translation Received Date:
Translations Received Date (B1 EP Publication):
Translations Received Date (B2 EP Publication):
Translations Received Date (B3 EP Publication):
Publication date:
20/03/2024
EP B1 Publication Date:
20/03/2024
EP B2 Publication Date:
EP B3 Publication Date:
Lapsed date:
Expiration date:
15/04/2039
Renunciation date:
Revocation date:
Annulment date:

Owner

From:
13/03/2024
 
 

Name:
Bristol-Myers Squibb Company
Address:
Route 206 & Province Line Road, Princeton, NJ 08543, United States (US)

Name:
Pfizer Inc.
Address:
66 Hudson Boulevard East, New York, NY 10001-2192, United States (US)

Agent

Name:
MARKS & CLERK LLP
From:
26/03/2024
Address:
BP 1775, 1017, LUXEMBOURG, Luxembourg (LU)
To:

Inventor

1

Name:
KUNTZ, Daniel
Address:
United States (US)

2

Name:
BADAWY, Sherif, Ibrahim, Farag
Address:
United States (US)

3

Name:
STEVENS, Timothy, D.
Address:
United States (US)

4

Name:
WAYBRANT, Brett
Address:
United States (US)

Priority

Priority Number:
201862658175 P
Priority Date:
16/04/2018
Priority Country:
United States (US)

Classification

IPC classification:
A61K 9/16; A61K 31/4545; A61P 7/02;

Publication

European Patent Bulletin

1

Issue number:
202412
Publication date:
20/03/2024
Description:
Grant (B1)

2

Issue number:
202504
Publication date:
22/01/2025
Description:
Opposition procedure started

3

Issue number:
202414
Publication date:
03/04/2024
Description:
Application number/publication number of the divisional application (Art. 76) changed

Annual Fees

Annual Fee Due Date:
30/04/2026
Annual Fee Number:
8
Annual Fee Amount:
99 Euro
Expected Payer:
Last Annual Fee Payment Date:
16/04/2025
Last Annual Fee Paid Number:
7
Last Annual Fee Paid Amount:
82 Euro
Payer:
CPA GLOBAL THE IP PLATFORM
Filing date Document type Number of pages
26/03/2024 Power Of Attorney 1
26/03/2024 Outgoing Correspondence 1